Veradigm Announces the Resignation of Board Director Beth Altman Due to Health Reasons
Veradigm (OTCMKTS: MDRX) announced that Beth Altman resigned from the Board of Directors on January 28, 2025, citing health reasons. Her departure is unrelated to any disagreements with company operations, policies, or practices and does not affect the ongoing restatement of 2022 financial statements.
Following Altman's resignation, who served as Audit Committee Chair since 2020, the Board appointed Greg Garrison as interim Audit Committee Chair. Garrison previously held this position from May 2016 through June 2022. The company is actively seeking stockholder input to identify qualified candidates for Board positions.
Veradigm (OTCMKTS: MDRX) ha annunciato che Beth Altman si è dimessa dal Consiglio di Amministrazione il 28 gennaio 2025, per motivi di salute. Le sue dimissioni non sono correlate a dissensi sulle operazioni, politiche o pratiche aziendali e non influenzano la riformulazione in corso dei bilanci finanziari del 2022.
Dopo le dimissioni di Altman, che ha ricoperto il ruolo di Presidente del Comitato di Revisione dal 2020, il Consiglio ha nominato Greg Garrison come Presidente ad interim del Comitato di Revisione. Garrison ha precedentemente ricoperto questa posizione da maggio 2016 a giugno 2022. L'azienda sta attivamente cercando input dagli azionisti per identificare candidati qualificati per le posizioni nel Consiglio.
Veradigm (OTCMKTS: MDRX) anunció que Beth Altman renunció a la Junta Directiva el 28 de enero de 2025, citando razones de salud. Su partida no está relacionada con desacuerdos sobre las operaciones, políticas o prácticas de la empresa y no afecta la reexpresión de los estados financieros de 2022 en curso.
Tras la renuncia de Altman, quien se desempeñó como Presidenta del Comité de Auditoría desde 2020, la Junta nombró a Greg Garrison como Presidente interino del Comité de Auditoría. Garrison ocupó previamente este puesto desde mayo de 2016 hasta junio de 2022. La empresa está buscando activamente la opinión de los accionistas para identificar candidatos calificados para las posiciones en la Junta.
Veradigm (OTCMKTS: MDRX)는 Beth Altman이 건강 문제로 인해 2025년 1월 28일 이사회에서 사임했다고 발표했습니다. 그녀의 사임은 회사 운영, 정책 또는 관행에 대한 어떤 이견과도 관련이 없으며 2022년 재무 제표의 재작성에도 영향을 미치지 않습니다.
2020년부터 감사 위원회 의장으로 재직해 온 Altman의 사임 후, 이사회는 Greg Garrison을 감사 위원회 의장 직무대행으로 임명했습니다. Garrison은 2016년 5월부터 2022년 6월까지 이 직책을 맡았습니다. 회사는 이사회 직위에 적합한 후보자를 식별하기 위해 주주들의 의견을 적극적으로 구하고 있습니다.
Veradigm (OTCMKTS: MDRX) a annoncé que Beth Altman a démissionné du Conseil d'administration le 28 janvier 2025, pour des raisons de santé. Son départ n'est pas lié à des désaccords concernant les opérations, politiques ou pratiques de l'entreprise et n'affecte pas la relecture en cours des états financiers de 2022.
Suite à la démission d'Altman, qui était présidente du Comité d'audit depuis 2020, le Conseil a nommé Greg Garrison comme président par intérim du Comité d'audit. Garrison a précédemment occupé ce poste de mai 2016 à juin 2022. L'entreprise recherche activement l'avis des actionnaires pour identifier des candidats qualifiés pour les postes au sein du Conseil.
Veradigm (OTCMKTS: MDRX) gab bekannt, dass Beth Altman am 28. Januar 2025 aus dem Vorstand zurückgetreten ist, aus gesundheitlichen Gründen. Ihr Rücktritt steht in keinem Zusammenhang mit Unstimmigkeiten über Unternehmensabläufe, -richtlinien oder -praktiken und beeinflusst auch nicht die laufende Neufassung der Finanzberichte von 2022.
Nach Altmans Rücktritt, die seit 2020 Vorsitzende des Prüfungsausschusses war, ernannte der Vorstand Greg Garrison zum kommissarischen Vorsitzenden des Prüfungsausschusses. Garrison hatte diese Position zuvor von Mai 2016 bis Juni 2022 inne. Das Unternehmen sucht aktiv nach den Meinungen der Aktionäre, um qualifizierte Kandidaten für Vorstandsposten zu identifizieren.
- None.
- Board disruption during ongoing financial restatement process
- Loss of experienced Audit Committee Chair during critical period
- Need to find replacement Board member indicates potential governance gap
Altman has been a valued advisor since 2020 and, as Audit Committee Chair, has been instrumental in helping the Company navigate a challenging period. Following Altman’s resignation, the Board appointed Greg Garrison to the Audit Committee of the Board and as interim Chair of the Audit Committee. Garrison previously served as the Chair of the Audit Committee from May 2016 through June 2022.
“On behalf of the entire Board, I thank Beth for the insight, dedication, and expertise that she brought to Veradigm,” said Greg Garrison, Chairman of the Board. “We are grateful for her valuable contributions and wish her all the best.”
Stockholder Input Welcomed on Board Refreshment
The Board is seeking input from stockholders in identifying highly qualified individuals with significant relevant experience to serve on the Board. Stockholders interested in submitting potential candidates should contact Jenny Gelinas, whose contact information is below.
About Veradigm®
Veradigm is a healthcare technology company that drives value through its unique combination of platforms, data, expertise, connectivity, and scale. The Veradigm Network features a dynamic community of solutions and partners providing advanced insights, technology, and data-driven solutions for the healthcare provider, payer, and biopharma markets. For more information about how Veradigm is fulfilling its mission of Transforming Health, Insightfully, visit www.veradigm.com, or find Veradigm on LinkedIn, Facebook, Twitter, Instagram, and YouTube.
© 2025 Veradigm LLC and/or its affiliates. All rights reserved. Cited marks are the property of Veradigm LLC and/or its affiliates. All other product or company names are the property of their respective holders, all rights reserved.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250130247934/en/
Investors:
Jenny Gelinas
312-506-1237
jenny.gelinas@veradigm.com
Media:
Concetta Rasiarmos
630-740-3152
concetta.rasiarmos@veradigm.com
Source: Veradigm
FAQ
Why did Beth Altman resign from Veradigm's (MDRX) Board of Directors?
Who replaced Beth Altman as Veradigm's (MDRX) Audit Committee Chair?
How will Altman's resignation affect Veradigm's (MDRX) 2022 financial restatement?
How is Veradigm (MDRX) handling the Board member replacement process?
